The WisdomTree BioRevolution Fund (WDNA) is a passively managed exchange-traded fund that seeks to track the WisdomTree BioRevolution Index, a modified equally weighted benchmark of developed-market companies positioned to be transformed by advancements in genetics and biotechnology. The fund generally uses a representative sampling strategy, investing in a subset of securities whose risk and return characteristics resemble the index as a whole.
The portfolio is dominated by health care, which typically accounts for roughly 88% to 93% of assets, with smaller allocations to basic materials and consumer staples reflecting agricultural, food, and industrial biology themes. Geographic exposure skews heavily toward the United States (roughly 85% or more), with modest exposure to developed Europe and Australia. The fund is classified as non-diversified and carries a net expense ratio of 0.45%.
Among the largest positions are names spanning established pharmaceutical leaders and high-growth biotech. Eli Lilly (LLY) anchors the metabolic-disease franchise, while Twist Bioscience (TWST), Moderna (MRNA), and 10x Genomics (TXG) provide exposure to synthetic biology, messenger RNA (mRNA) therapeutics, and genomics tools. Diagnostic and data names such as Natera (NTRA) and Tempus AI (TEM) represent the growing precision-medicine layer, while Thermo Fisher Scientific (TMO) offers diversified life-science infrastructure. This mix positions the fund across the full biotech value chain, from drug discovery to diagnostics and agricultural inputs.
Several events could materially shape WDNA's trajectory over the coming quarters:
The macro environment is pivotal for a portfolio so concentrated in innovation-driven health care. Biotechnology valuations are inversely related to long-term interest rates, because much of their value lies in future cash flows; a higher-for-longer rate backdrop tends to compress valuations, while rate cuts historically ease financing conditions for capital-intensive drug developers. Inflation trends also matter indirectly, affecting both borrowing costs and the pricing environment for pharmaceuticals and agricultural products.
On the sector outlook, the long-term case for genomics and precision medicine remains intact, supported by falling sequencing costs, growing adoption of molecular diagnostics, and expanding therapeutic applications. The agricultural biology and food-ingredient sleeve, exposed through names such as Corteva (CTVA) and Darling Ingredients (DAR), ties the fund to global food demand and sustainability themes. Because the underlying index is equally weighted, market trends favoring mega-cap drugmakers over smaller biotech can shift relative performance, underscoring the importance of breadth in the portfolio exposure.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders and investors assess whether an asset such as a stock or ETF may trend bullish, bearish, or sideways over the coming week or month. By analyzing historical price patterns and developing momentum, the tool aims to surface potential breakouts, reversals, or consolidation phases before they fully materialize. Users can explore predictions across a wide range of tradable instruments, review searchable prediction categories with historical context, and set up alert-oriented functionality to stay informed of shifting conditions. For those monitoring evolving themes in biotechnology and genomics, the Trend Prediction Engine can serve as a complementary lens on near-term directional signals alongside fundamental analysis.
Over the long term, WDNA's trajectory is tied to durable structural themes rather than short-term market cycles. Advances in gene editing, cell therapy, mRNA platforms, and synthetic biology continue to broaden the addressable market for the underlying companies. Demographic trends, including an aging global population and rising chronic-disease burden, support sustained demand for innovative therapeutics and diagnostics. Meanwhile, the convergence of biology with computing power is fueling the growth of AI-driven drug discovery and genomics-data platforms, potentially lowering development costs and accelerating product pipelines.
These structural tailwinds must be balanced against cyclical realities. Biotechnology is a capital-intensive sector whose funding environment ebbs and flows with interest-rate cycles and venture-capital activity. A prolonged high-rate environment could constrain early-stage innovation, while easing financial conditions could reinvigorate the clinical-stage segment that forms a meaningful share of the fund's mid- and small-cap sleeve. Market structure changes, such as the growth of passive thematic investing and evolving regulatory frameworks for novel therapies, may also shape how capital flows into bio-revolution exposures over time. Investors evaluating this ETF forecast should weigh both the long-run innovation opportunity and the inherent volatility of a non-diversified, health-care-centric portfolio.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MCOW | 21.49 | N/A | N/A |
| Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) | |||
| HDG | 51.83 | -0.68 | -1.29% |
| ProShares Hedge Replication ETF (HDG) | |||
| KJAN | 43.48 | -0.79 | -1.79% |
| Innovator U.S. Small Cap Power Buffer ETF - January (KJAN) | |||
| EXUS | 24.00 | -0.64 | -2.58% |
| Nomura ETF Trust Nomura Focused International Core ETF (EXUS) | |||
| FSEP | 53.42 | -1.46 | -2.67% |
| FT Vest U.S. Equity Buffer ETF - September (FSEP) | |||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FSEP | 53.42 | -1.46 | -2.67% |
| FT Vest U.S. Equity Buffer ETF - September (FSEP) | |||
| EXUS | 24.00 | -0.64 | -2.58% |
| Nomura ETF Trust Nomura Focused International Core ETF (EXUS) | |||
| KJAN | 43.48 | -0.79 | -1.79% |
| Innovator U.S. Small Cap Power Buffer ETF - January (KJAN) | |||
| HDG | 51.83 | -0.68 | -1.29% |
| ProShares Hedge Replication ETF (HDG) | |||
| MCOW | 21.49 | N/A | N/A |
| Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW) | |||
A.I.dvisor tells us that WDNA and XBI have been poorly correlated (+-1% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that WDNA and XBI's prices will move in lockstep.
| Ticker / NAME | Correlation To WDNA | 1D Price Change % | ||
|---|---|---|---|---|
| WDNA | 100% | -3.12% | ||
| XBI - WDNA | -1% Poorly correlated | -2.73% | ||
| IBB - WDNA | -3% Poorly correlated | -2.05% | ||
| XLV - WDNA | -5% Poorly correlated | -0.12% | ||
| IYH - WDNA | -5% Poorly correlated | -0.32% | ||
| VHT - WDNA | -5% Poorly correlated | -0.40% | ||
More | ||||
WDNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 46 of 53 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 87%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WDNA as a result. In 58 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for WDNA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day moving average for WDNA crossed bearishly below the 50-day moving average on November 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where WDNA advanced for three days, in 213 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
WDNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 200 of 239 cases where WDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.